



Fact Sheet

The GeneSight Psychotropic test from Myriad Neuroscience is the category-leading pharmacogenomic test for certain medications primarily used to treat depression, anxiety and other psychiatric conditions. The GeneSight test analyzes clinically important genetic variations in a patient's DNA, which can inform about gene-drug interactions that may impact how individuals metabolize or respond to these medications. The GeneSight test has been used by tens of thousands of physicians for more than one million patients to provide genetic information that is unique to each person.

GeneSight Test Panels

- The GeneSight Psychotropic test identifies an individual's genetic variations that may impact how they metabolize or respond to medications commonly prescribed to treat depression, anxiety and other psychiatric conditions.
- The GeneSight MTHFR test analyzes whether an individual has variation in MTHFR, which may limit their ability to create L-methylfolate

Helping with Trial-and-Error Depression Treatment

Trial-and-error prescribing for depression can cause frustration, wasted time, wasted money, and wasted medication for physicians and patients. According to a large study:

- Less than 40% of study participants achieved remission with their first depression medication
- Only 31% of people became symptom-free with their second medication trial
- Only 14% became symptom-free after their third medication trial.¹

From Sample Collection to Results in Days

The process is simple:

- A cheek swab is used to collect a sample of a patient's DNA
- Swabs are sent to our CLIA- and CAP-certified lab in prepaid FedEx envelopes
- About 2 days after we receive the sample, healthcare providers can access a patient's personalized report on their secure GeneSight portal

Backed by Multiple Clinical Studies

The clinical validity, clinical utility, and economic utility of the GeneSight Psychotropic test have been evaluated in more peer-reviewed publications than any other test in its category. In fact, it's the only neuropsychiatric pharmacogenomic test backed by such extensive research. While not all patients experienced improved outcomes, overall, the GeneSight Psychotropic test helped improve outcomes compared to treatment as usual in multiple clinical studies. To read more about our clinical studies, please visit genesight.com/for-clinicians/.

Resources Available

Our team of PharmDs, PhDs, MDs, and genetic counselors is available to answer any questions physicians or patients may have about the GeneSight test. We can be reached at medinfo@myriad.com, or by phone at 855.891.9415. To order the GeneSight test, contact our sales team through genesight.com/take-the-next-step.

¹ Rush, et al, *The American Journal of Psychiatry*. 2006 Nov; 163(11):1905-17